Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?

Abstract

Liver resection is the most effective treatment for hepatocellular carcinoma (HCC). The Barcelona Clinic Liver Cancer (BCLC) staging system is commonly accepted as a guideline for HCC treatment, but it only recommends liver resection for the patients with HCC at stage 0 to A1. The surgical indications of the BCLC staging system need to be re-evaluated. 120 HCC patients undergoing curative liver resection were retrospectively stratified to the BCLC staging system, and the survival of the patients at stages A, B and C was analyzed. The justification of the BCLC staging system was re-evaluated. Fifty-two patients were classified at stage A, 51 at stage B and 17 at stage C respectively. The hospital mortality of this cohort was zero and the morbidity was 24.1%. The 1-, 2-, 3-year overall survival rate of this cohort was 81.6%, 68.3%, and 57.5% respectively. There was no significant difference in the survival rate between the patients at stage A and B (P>0.05). If the treatment guidelines of BCLC staging system were followed, the majority of the patients at stages A and B (77.7%, 80/103) would not have been treated surgically. Our data suggest that the surgical indications of the BCLC staging system are not justified for HCC treatment. More studies may be needed as for how to further broaden the surgical indications of the BCLC staging system in the future.

Keywords

BCLC staging system / liver cirrhosis / liver resection / survival Shuang

References

[1] LlovetJ.M., BurroughsA., BruixJ.. Hepatocellular car cinoma. Lancet, 2003, 362(9399): 1907-1917

[2] ParkinD.M., BrayF., FerlayJ., et al.. Estimating the world cancer burden: Globocan 2000. Int J Cancer, 2001, 94(2): 153-156

[3] ChenX.P., HuangZ.Y.. Surgical treatment of hepatocellular carcinoma in China: surgical techniques, indications, and outcomes. Langenbecks Arch Surg, 2005, 390(3): 259-265

[4] BruixJ., ShermanM.. Management of hepatocellular carcinoma. Hepatology, 2005, 42(5): 1208-1236

[5] VautheyJ.N., LauwersG.Y., EsnaolaN.F., et al.. Simplified staging for hepatocellular carcinoma. J Clin Oncol, 2002, 20(6): 1527-1536

[6] OkudaK., OhtsukiT., ObataH., et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 1985, 56(4): 918-928

[7] KudoM., ChungH., OsakiY.. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol, 2003, 38(3): 207-215

[8] A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 1998,28(3):751–755

[9] LeungT.W., TangA.M., ZeeB., et al.. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer, 2002, 94(6): 1760-1769

[10] LlovetJ.M., BruC., BruixJ.. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 1999, 19(3): 329-338

[11] ChevretS., TrinchetJ.C., MathieuD., et al.. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol, 1999, 31(1): 133-141

[12] VillaE., ColantoniA., CammaC., et al.. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol, 2003, 21(3): 441-446

[13] WangJ.H., ChangchienC.S., HuT.H., et al.. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-Survival analysis of 3892 patients. Eur J Cancer, 2008, 44(7): 1000-1006

[14] CilloU., BassanelloM., VitaleA., et al.. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. J Hepatol, 2004, 40(1): 124-131

[15] CilloU., VitaleA., GrigolettoF., et al.. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol, 2006, 44(4): 723-731

[16] BefelerA.S., Di BisceglieA.M.. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 2002, 122(6): 1609-1619

[17] TorzilliG., DonadonM., MarconiM., et al.. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg, 2008, 143(11): 1082-1090

[18] VitaleA., SaracinoE., BoccagniP., et al.. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc, 2009, 41(4): 1260-1263

[19] IshizawaT., HasegawaK., AokiT., et al.. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology, 2008, 134(7): 1908-1916

[20] MarreroJ.A.. Staging systems for hepatocellular carcinoma: should we all use the BCLC system?. J Hepatol, 2006, 44(4): 630-632

[21] BilimoriaM.M., LauwersG.Y., DohertyD.A., et al.. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg, 2001, 136(5): 528-535

[22] HuangZ.Y., ChenG., HaoX.Y., et al.. Outcomes of non-anatomic liver resection for hepatocellular carcinoma in the patients with liver cirrhosis and analysis of prognostic factors. Langenbecks Arch Surg, 2011, 396(2): 193-199

[23] ChoiS.B., LeeJ.G., KimK.S., et al.. The prognosis and survival analysis according to seven staging systems of hepatocellular carcinoma following curative resection. Hepatogastroenterology, 2008, 55(88): 2140-2145

[24] ChenC.H., HuF.C., HuangG.T., et al.. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. Eur J Cancer, 2010, 200945(9): 1630-1639

[25] KondoK., ChijiiwaK., NaganoM., et al.. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology, 2007, 54(77): 1534-1538

[26] ItoK., MitchellD.G., HannH.W., et al.. Viral-induced cirrhosis: grading of severity using MR imaging. Am J Roentgenol, 1999, 173(3): 591-596

[27] LiY.M., LvF., XuX., et al.. Evaluation of liver functional reserve by combining D-sorbitol clearance rate and CT measured liver volume. World J Gastroenterol, 2003, 9(9): 2092-2095

[28] NgK.K., VautheyJ.N., PawlikT.M., et al.. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol, 2005, 12(5): 364-373

[29] LoC.M., NganH., TsoW.K., et al.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5): 1164-1171

[30] KonishiM., RyuM., KinoshitaT., et al.. Surgical treatment of hepatocellular carcinoma with direct removal of the tumor thrombus in the main portal vein. Hepatogastroenterology, 2001, 48(41): 1421-1424

[31] ShuqunC., MengchaoW., HanC., et al.. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. Hepatogastroenterology, 2007, 54(74): 499-502

[32] FanJ., WuZ.Q., TangZ.Y., et al.. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol, 2001, 7(1): 28-32